Rivals swoop in after report batters diabetes drug Avandia.(GlaxoSmithKline's drug Avandia increases heart-attack risk)

Advertising Age, May, 2007 by THOMASELLI, RICH

Byline: RICH THOMASELLI

editor@adage.com

pharmaceutical players jockeying for leverage in the ultra-competitive $10 billion diabetes market are poised to pounce on a report that GlaxoSmithKline's powerhouse drug Avandia increases heart-attack risk.

Hot on the heels of last week's report from the influential New England Journal of Medicine said Avandia raised heart-attack risk 43%, drug giants such as Eli Lilly and Merck are ramping up marketing for their competitive products.

In a research note, Morgan Stanley analyst Jami Rubin wrote that the Avandia news will likely benefit Eli Lilly's Byetta and Merck's Januvia and Janumet. The analyst predicted a "significant portion'' of Avandia's 2007 projected revenue of $3 billion will go...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
  • Click Here
advertisement